title: Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor-1α, suppress amyloid β-induced neurotoxicity.
abstract: Alzheimer's disease (AD) is characterized by a progressive cognitive decline and accumulation of neurotoxic oligomeric peptides amyloid-β (Aβ). Although the molecular events are not entirely known, it has become evident that inflammation, environmental and other risk factors may play a causal, disruptive and/or protective role in the development of AD. The present study investigated the ability of the chemokines, macrophage inflammatory protein-2 (MIP-2) and stromal cell-derived factor-1α (SDF-1α), the respective ligands for chemokine receptors CXCR2 and CXCR4, to suppress Aβ-induced neurotoxicity in vitro and in vivo. Pretreatment with MIP-2 or SDF-1α significantly protected neurons from Aβ-induced dendritic regression and apoptosis in vitro through activation of Akt, ERK1/2 and maintenance of metalloproteinase ADAM17 especially with SDF-1α. Intra-cerebroventricular (ICV) injection of Aβ led to reduction in dendritic length and spine density of pyramidal neurons in the CA1 area of the hippocampus and increased oxidative damage 24h following the exposure. The Aβ-induced morphometric changes of neurons and increase in biomarkers of oxidative damage, F(2)-isoprostanes, were significantly inhibited by pretreatment with the chemokines MIP-2 or SDF-1α. Additionally, MIP-2 or SDF-1α was able to suppress the aberrant mislocalization of p21-activated kinase (PAK), one of the proteins involved in the maintenance of dendritic spines. Furthermore, MIP-2 also protected neurons against Aβ neurotoxicity in CXCR2-/- mice, potentially through observed up regulation of CXCR1 mRNA. Understanding the neuroprotective potential of chemokines is crucial in defining the role for their employment during the early stages of neurodegeneration.
authors.affiliation: Department of Cancer Biology, Vanderbilt University, School of Medicine, Nashville, TN 37232, USA.
authors.forename: Dayanidhi
authors.initials: D
authors.lastname: Raman
authors.forename: Snjezana-Zaja
authors.initials: SZ
authors.lastname: Milatovic
authors.forename: Dejan
authors.initials: D
authors.lastname: Milatovic
authors.forename: Ryan
authors.initials: R
authors.lastname: Splittgerber
authors.forename: Guo-Huang
authors.initials: GH
authors.lastname: Fan
authors.forename: Ann
authors.initials: A
authors.lastname: Richmond
mesh_terms: D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000633:toxicity; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001921:Brain / Q000187:drug effects*; D054377:Chemokine CXCL12 / Q000494:pharmacology*; D054426:Chemokine CXCL2 / Q000494:pharmacology*; D018925:Chemokines / Q000494:pharmacology*; D028441:F2-Isoprostanes / Q000032:analysis; D051379:Mice; D008810:Mice, Inbred C57BL; D009474:Neurons / Q000737:chemistry / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology*; D020258:Neurotoxicity Syndromes / Q000209:etiology / Q000517:prevention & control; D060888:Real-Time Polymerase Chain Reaction; D023063:Receptors, Interleukin-8B / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D054377:Chemokine CXCL12; D054426:Chemokine CXCL2; D018925:Chemokines; D028441:F2-Isoprostanes; D018696:Neuroprotective Agents; D023063:Receptors, Interleukin-8B